{"cells":[{"cell_type":"code","source":[" dbutils.fs.ls(\"FileStore/tables\")  "],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"7bb1248d-8f3c-4321-b8c3-ad5cba1acf5a","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[1]: [FileInfo(path='dbfs:/FileStore/tables/FaultDataset.csv', name='FaultDataset.csv', size=1703184, modificationTime=1678793904000),\n FileInfo(path='dbfs:/FileStore/tables/Occupancy_Detection_Data.csv', name='Occupancy_Detection_Data.csv', size=50968, modificationTime=1677674814000),\n FileInfo(path='dbfs:/FileStore/tables/account-models/', name='account-models/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/accounts/', name='accounts/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1675262155000),\n FileInfo(path='dbfs:/FileStore/tables/activations/', name='activations/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/activations.zip', name='activations.zip', size=8411369, modificationTime=1675257098000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019/', name='clinicaltrial_2019/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1682414831000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.zip', name='clinicaltrial_2019.zip', size=9707871, modificationTime=1682252672000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020/', name='clinicaltrial_2020/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1682414836000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.zip', name='clinicaltrial_2020.zip', size=10599182, modificationTime=1682252739000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021/', name='clinicaltrial_2021/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1682414840000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.zip', name='clinicaltrial_2021.zip', size=11508457, modificationTime=1682252805000),\n FileInfo(path='dbfs:/FileStore/tables/flood.csv', name='flood.csv', size=129985, modificationTime=1676474828000),\n FileInfo(path='dbfs:/FileStore/tables/iotstream/', name='iotstream/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/iotstream.zip', name='iotstream.zip', size=43891, modificationTime=1677076100000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1675262184000),\n FileInfo(path='dbfs:/FileStore/tables/movies.csv', name='movies.csv', size=494431, modificationTime=1678283585000),\n FileInfo(path='dbfs:/FileStore/tables/myratings.csv', name='myratings.csv', size=10683, modificationTime=1678283605000),\n FileInfo(path='dbfs:/FileStore/tables/pharma/', name='pharma/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1682414841000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.zip', name='pharma.zip', size=109982, modificationTime=1682252615000),\n FileInfo(path='dbfs:/FileStore/tables/ratings.csv', name='ratings.csv', size=2483723, modificationTime=1678283548000),\n FileInfo(path='dbfs:/FileStore/tables/webpage/', name='webpage/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1675863628000)]"]}],"execution_count":0},{"cell_type":"code","source":["rdd_clinicaltrial_2021=sc.wholeTextFiles('/FileStore/tables/clinicaltrial_2021.csv/')\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"2e080ae3-69c7-4bdf-82bb-ce043eac4176","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["rdd_clinicaltrial_2021.take(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"09c3daee-ff3d-414f-a96f-8fd25dffe3c1","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[4]: [('dbfs:/FileStore/tables/clinicaltrial_2021.csv',\n  \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT0\n\n*** WARNING: max output size exceeded, skipping output. ***\n\niversity of Kansas Medical Center|Recruiting|Jan 2021|Jun 2022|Interventional|Sep 2020|Diabetes,Diabetes Mellitus|\\r\\nNCT04577729|Medical University of Graz|Recruiting|May 2021|Jul 2024|Interventional|Sep 2020|Melanoma|\\r\\nNCT04577196|University Hospital, Grenoble|Not yet recruiting|Nov 2020|Feb 2022|Observational [Patient Registry]|Sep 2020|Critical Illness,Wounds and Injuries|\\r\\nNCT04575064|Professor Dr. Bernd Mühlbauer|Active, not recruiting|Jun 2020|Nov 2022|Interventional|Sep 2020|COVID-19|Remdesivir\\r\\nNCT04578067|University of Oslo|Recruiting|Sep 2020|Dec 2023|Interventional|Sep 2020|Hypercholesterolemia,Body Weight,Body Weight Changes|\\r\\nNCT04577807|Istari Oncology, Inc.|Recruiting|Nov 2020|May 2023|Interventional|Sep 2020|Melanoma|\\r\\nNCT04574713|St. Olavs Hospital|Recruiting|Apr 2020|Oct 2024|Interventional|Sep 2020|Migraine Disorders|Candesartan,Candesartan cilexetil\\r\\nNCT04578496|Clinuvel Pharmaceuticals Limited|Completed|Jul 2011|Feb 2014|Interventional|Oct 2020|Protoporphyria|Afamelanotide\\r\\nNCT04576546|Lo.Li.Pharma s.r.l|Recruiting|Nov 2020|Sep 2021|Interventional|Sep 2020||Inositol\\r\\nNCT04579952|Istituto Ortopedico Rizzoli|Enrolling by invitation|Jan 2021|Dec 2022|Interventional|Sep 2020|Chronic Pain|\\r\\nNCT04577846|Aga Khan University|Not yet recruiting|Nov 2020|Dec 2022|Interventional|Oct 2020|Infections,Surgical Wound Infection|Cephalexin\\r\\nNCT04575857|University of Washington|Not yet recruiting|Dec 2021|Dec 2022|Observational|Sep 2020|Rheumatic Heart Disease,Rheumatic Diseases,Heart Diseases|Atorvastatin\\r\\nNCT04574596|Duke University|Completed|Nov 2020|Jun 2021|Observational|Sep 2020|Escherichia coli Infections|\\r\\nNCT04575740|Brigham and Women's Hospital|Recruiting|Sep 2020|Jun 2024|Interventional|Sep 2020|Apnea,Sleep Apnea Syndromes|\\r\\nNCT04572503|Benha University|Recruiting|Oct 2020|Dec 2021|Interventional|Sep 2020|Apnea,Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT04577157|Universiti Putra Malaysia|Recruiting|Jan 2021|Nov 2021|Interventional|May 2020||\\r\\nNCT04574830|Ultragenyx Pharmaceutical Inc|Recruiting|Nov 2020|Feb 2022|Observational|Sep 2020|Glycogen Storage Disease,Glycogen Storage Disease Type III,Metabolic Diseases|\\r\\nNCT04577859|St. George's Hospital, London|Not yet recruiting|Jan 2021|Jan 2023|Interventional|Sep 2020|Esophageal Fistula,Atrial Fibrillation,Fistula|\\r\\nNCT04576845|Saglik Bilimleri Universitesi|Not yet recruiting|Oct 2020|Nov 2020|Observational|Sep 2020|Hypersensitivity,Milk Hypersensitivity,Growth Disorders|\\r\\nNCT04573634|Jill M Kolesar|Active, not recruiting|May 2020|Dec 2023|Observational|Sep 2020|COVID-19,Severe Acute Respiratory Syndrome|\\r\\nNCT04579536|King Abdulaziz University|Recruiting|Feb 2019|Jul 2021|Interventional|Oct 2020||\\r\\nNCT04577690|The Hospital for Sick Children|Recruiting|Dec 2019|Jan 2022|Interventional|Sep 2020|Pain|Epinephrine,Racepinephrine,Bupivacaine,Epinephryl borate\\r\\nNCT04573842|Karolinska Institutet|Recruiting|Nov 2020|Oct 2021|Observational|Sep 2020|Hypotension,Hypovolemia|\\r\\nNCT04577677|KU Leuven|Recruiting|Sep 2020|Dec 2024|Interventional|Sep 2020||\\r\\nNCT04572841|Sanofi|Recruiting|Nov 2020|Oct 2022|Interventional|Sep 2020|Sjogrens Syndrome,Syndrome|\\r\\nNCT04572399|Cedars-Sinai Medical Center|Completed|Oct 2020|Dec 2020|Interventional|Sep 2020|Coronavirus Infections|\\r\\nNCT04570696|CHU de Reims|Recruiting|Jul 2019|Jun 2021|Observational|Sep 2020|Hemophilia A|\\r\\nNCT04571931|Cairo University|Not yet recruiting|Feb 2021|Jul 2021|Observational|Sep 2020|Dental Caries|\\r\\nNCT04570735|Poitiers University Hospital|Recruiting|Oct 2020|Oct 2021|Observational|Sep 2020|Kidney Diseases,Diabetic Nephropathies|\\r\\nNCT04577599|Daniel Carrizosa|Recruiting|Jan 2021|Oct 2023|Interventional|Sep 2020|Lung Neoplasms|\\r\\nNCT04573946|Brigham and Women's Hospital|Active, not recruiting|Jul 2019|Jun 2023|Interventional|Sep 2020||Vitamin D,Ergocalciferols,Cholecalciferol,Vitamins\\r\\nNCT04577404|Mitsubishi Tanabe Pharma Development America, Inc.|Recruiting|Oct 2020|Sep 2023|Interventional|Sep 2020|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|Edaravone\\r\\nNCT04575246|Aga Khan University|Completed|Jan 2016|Dec 2017|Observational|Sep 2020|Hypothermia|\\r\\nNCT04579757|Hutchison Medipharma Limited|Recruiting|Mar 2021|Apr 2023|Interventional|Sep 2020|Neoplasms,Sarcoma,Small Cell Lung Carcinoma,Neuroendocrine Tumors,Thyroid Carcinoma|\\r\\nNCT04575311|Arcus Biosciences, Inc.|Recruiting|Oct 2020|Nov 2021|Interventional|Sep 2020||\\r\\nNCT04575168|Spartan Bioscience Inc.|Completed|Oct 2020|Dec 2020|Observational|Oct 2020|COVID-19|\\r\\nNCT04574778|Rothman Institute Orthopaedics|Enrolling by invitation|Mar 2021|Oct 2021|Interventional|Sep 2020|Pain|Acetaminophen\\r\\nNCT04570033|Military Institute of Medicine, Poland|Completed|Jan 2016|Jan 2020|Interventional|Sep 2020|Adenoma,Parathyroid Neoplasms,Hyperparathyroidism|Parathyroid Hormone\\r\\nNCT04572854|Apellis Pharmaceuticals, Inc.|Recruiting|Feb 2021|Sep 2022|Interventional|Sep 2020|Glomerulonephritis,Recurrence|\\r\\nNCT04572282|Associacao de Investigacao de Cuidados de Suporte em Oncologia|Not yet recruiting|Feb 2021|Apr 2021|Interventional|Sep 2020||\\r\\nNCT04576234|Sarah Asmaa|Not yet recruiting|Sep 2020|Dec 2020|Interventional|Aug 2020||\\r\\nNCT04574635|Mayo Clinic|Recruiting|Nov 2020|Nov 2024|Observational|Sep 2020|Carcinoma,Uterine Cervical Neoplasms,Papilloma|\\r\\nNCT04579146|Hôpital Européen Marseille|Recruiting|Sep 2020|Oct 2023|Observational|Sep 2020|HIV Infections|\\r\\nNCT04575818|Galapagos NV|Terminated|Sep 2020|Apr 2021|Interventional|Sep 2020||\\r\\nNCT04576494|CHU de Reims|Not yet recruiting|Dec 2020|May 2024|Interventional|Sep 2020|Muscular Atrophy,Atrophy|\\r\\nNCT04573166|China National Center for Cardiovascular Diseases|Recruiting|Sep 2020|Jan 2022|Interventional|Sep 2020|Heart Failure|\\r\\nNCT04570475|The University of Texas Health Science Center, Houston|Recruiting|Sep 2021|Jun 2024|Interventional|Sep 2020|Cluster Headache,Headache|Vitamin D\\r\\nNCT04574466|University of Zurich|Recruiting|Aug 2020|Jun 2022|Interventional|Sep 2020|Depression|\\r\\nNCT04572204|Assiut University|Active, not recruiting|Oct 2020|Oct 2022|Observational|Sep 2020|Wounds and Injuries|\\r\\nNCT04574492|AbbVie|Recruiting|Oct 2020|Sep 2024|Observational|Sep 2020|Arthritis|\\r\\nNCT04575493|Islamia University of Bahawalpur|Completed|Oct 2020|Nov 2020|Interventional|Sep 2020|Infections,Communicable Diseases,Urinary Tract Infections|Ciprofloxacin\\r\\nNCT04575519|Fundació Institut Germans Trias i Pujol|Recruiting|Mar 2021|Jun 2025|Interventional|Aug 2020|Tuberculosis,Latent Tuberculosis|Aspirin,Ibuprofen\\r\\nNCT04571034|Jeffrey Sykora|Completed|Feb 2021|Jul 2021|Interventional|Sep 2020||\\r\\nNCT04579237|National Institutes of Health Clinical Center (CC)|Active, not recruiting|Oct 2020|Jun 2030|Observational|Oct 2020||\\r\\nNCT04572412|Lancashire Teaching Hospitals NHS Foundation Trust|Recruiting|Nov 2020|Jun 2022|Interventional|Sep 2020|COVID-19,Pneumonia|\\r\\nNCT04576130|Rigshospitalet, Denmark|Recruiting|Oct 2020|Oct 2032|Interventional|Sep 2020|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Tachycardia,Out-of-Hospital Cardiac Arrest,Ventricular Fibrillation|\\r\\nNCT04573140|University of Florida|Recruiting|Oct 2021|Oct 2022|Interventional|Sep 2020|Glioblastoma|\\r\\nNCT04573413|Azienda Usl di Bologna|Recruiting|Mar 2021|Mar 2023|Interventional|Sep 2020|Brain Injuries,Perceptual Disorders,Wounds and Injuries|\\r\\nNCT04570423|Spectrum Pharmaceuticals, Inc|Recruiting|May 2021|Oct 2025|Interventional|Sep 2020|Lymphoma|\\r\\nNCT04579419|King Abdulaziz Medical City|Completed|Nov 2019|Aug 2020|Interventional|Sep 2020||\\r\\nNCT04572568|Beijing Tiantan Hospital|Recruiting|Apr 2019|Apr 2024|Observational [Patient Registry]|Sep 2020|Hemangioma,Intracranial Arteriovenous Malformations,Arteriovenous Malformations,Congenital Abnormalities|\\r\\nNCT04574960|University Health Network, Toronto|Recruiting|Feb 2021|Feb 2025|Interventional|Sep 2020|Carcinoma|Gemcitabine,Carboplatin\\r\\nNCT04578990|Jordi Gol i Gurina Foundation|Not yet recruiting|Mar 2021|Aug 2023|Interventional|Sep 2020|Peripheral Arterial Disease,Peripheral Vascular Diseases,Arteriosclerosis|\\r\\nNCT04578249|West Virginia University|Recruiting|Jul 2021|Sep 2021|Interventional|Jul 2020|Chronobiology Disorders|\\r\\nNCT04575116|Pfizer|Completed|Sep 2020|Feb 2021|Interventional|Sep 2020||\\r\\nNCT04571385|Acesion Pharma|Recruiting|Sep 2019|Jan 2022|Interventional|Sep 2020|Atrial Fibrillation|\\r\\nNCT04576338|Auburn University|Enrolling by invitation|Jan 2020|May 2023|Observational|Sep 2020||\\r\\nNCT04578314|University of Hamburg-Eppendorf|Recruiting|Oct 2020|Mar 2023|Interventional|Sep 2020|Hallucinations,Schizophrenia,Psychotic Disorders,Mental Disorders|\\r\\nNCT04575259|Anavex Life Sciences Corp.|Recruiting|Oct 2019|Oct 2021|Interventional|Sep 2020|Parkinson Disease,Dementia|\\r\\nNCT04570956|Amy C. Degnim|Recruiting|Jul 2021|Dec 2026|Interventional|Sep 2020|Carcinoma,Carcinoma in Situ,Breast Carcinoma In Situ,Hyperplasia|Tamoxifen,Afimoxifene\\r\\nNCT04574102|Omega Ophthalmics|Active, not recruiting|Feb 2021|Dec 2021|Interventional|Sep 2020|Cataract|\\r\\nNCT04571242|SGX Nova LLC|Recruiting|Sep 2020|Jan 2023|Interventional|Sep 2020|Back Pain|\\r\\nNCT04570566|Ain Shams University|Completed|May 2016|May 2017|Interventional|Sep 2020||\\r\\nNCT04576559|King Abdulaziz University|Recruiting|Sep 2019|Aug 2021|Interventional|Sep 2020|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT04573569|University of Minnesota|Completed|Mar 2018|Jun 2019|Observational|Dec 2018|Epilepsy|\\r\\nNCT04574895|Vanderbilt University Medical Center|Recruiting|Nov 2020|Nov 2022|Interventional|Sep 2020|Pulmonary Embolism,Thrombosis,Embolism,Thromboembolism,Venous Thromboembolism,Venous Thrombosis|\\r\\nNCT04578743|ANSwers Neuroscience, Inc.|Recruiting|Oct 2020|Sep 2023|Interventional|Oct 2020|Brain Injuries,Brain Concussion|\\r\\nNCT04577417|Nemours Children's Clinic|Recruiting|Sep 2020|Jun 2021|Observational|Sep 2020|Hyperkinesis,Disease,Attention Deficit Disorder with Hyperactivity|Methylphenidate,Amphetamine,Adderall,Dextroamphetamine,Dexmethylphenidate Hydrochloride\\r\\nNCT04573699|BackBeat Medical Inc|Recruiting|Dec 2020|Jan 2022|Observational|Sep 2020|Heart Failure|\\r\\nNCT04570774|Samsung Medical Center|Recruiting|Sep 2020|Nov 2021|Interventional|Sep 2020|Stroke|\\r\\nNCT04571333|MED-EL Elektromedizinische Geräte GesmbH|Active, not recruiting|Sep 2020|Mar 2022|Interventional|Sep 2020|Hearing Loss,Deafness|\\r\\nNCT04576221|Ahmed talaat ahmed aly|Completed|Jan 2020|Sep 2020|Interventional|Aug 2020|Pneumonia,Respiratory Aspiration|\\r\\nNCT04570228|SoniVie Inc.|Not yet recruiting|Jun 2021|Dec 2025|Interventional|Sep 2020|Pulmonary Arterial Hypertension,Familial Primary Pulmonary Hypertension,Hypertension|\\r\\nNCT04572594|Sun Yat-sen University|Recruiting|Jan 2020|Jan 2021|Observational|Sep 2020||\\r\\nNCT04571047|Sahlgrenska University Hospital, Sweden|Recruiting|Oct 2020|Aug 2021|Observational [Patient Registry]|Sep 2020|Colorectal Neoplasms|\\r\\nNCT04573127|Central Hospital, Nancy, France|Active, not recruiting|Jul 2020|Nov 2021|Observational|Aug 2020|Depressive Disorder,Gender Dysphoria|\\r\\nNCT04571073|Eisenhower Army Medical Center|Completed|Mar 2018|Mar 2019|Interventional|Sep 2020|Fasciitis|\\r\\nNCT04574674|University of Glasgow|Recruiting|Dec 2020|Dec 2021|Interventional|Sep 2020||\\r\\nNCT04577313|University of Connecticut|Recruiting|Sep 2020|Nov 2024|Interventional|Sep 2020|HIV Infections|\\r\\nNCT04576286|Ain Shams University|Recruiting|Jul 2020|Aug 2021|Interventional|Sep 2020|Urinary Bladder Neoplasms|\\r\\nNCT04571580|Ge Junbo|Recruiting|Jul 2021|Oct 2022|Interventional|Sep 2020|Myocardial Infarction,ST Elevation Myocardial Infarction,Infarction|Reteplase,Tissue Plasminogen Activator\\r\\nNCT04577651|Boston Scientific Corporation|Recruiting|Nov 2020|Oct 2026|Interventional|Sep 2020|Parkinson Disease|\\r\\nNCT04570098|Charite University, Berlin, Germany|Recruiting|Jul 2020|Dec 2023|Observational|Sep 2020|Heart Failure,Tricuspid Valve Insufficiency|\\r\\nNCT04578535|Baxalta now part of Shire|Recruiting|Oct 2020|Sep 2021|Interventional|Jul 2020||Immunoglobulins\\r\\nNCT04571567|Andrew Alexis, MD|Enrolling by invitation|Dec 2019|Apr 2022|Interventional|Sep 2020|Psoriasis|\\r\\nNCT04575805|Dokuz Eylul University|Completed|Sep 2020|Mar 2021|Interventional|Sep 2020|Compulsive Personality Disorder,Obsessive-Compulsive Disorder,Compulsive Behavior|\\r\\nNCT04573426|Ohio State University|Completed|Nov 2019|May 2021|Observational|Sep 2020|Overweight|Acetaminophen\\r\\nNCT04579744|Hospital Angeles del Pedregal|Completed|May 2020|Sep 2020|Observational|Sep 2020|Granuloma,Foreign Bodies|\\r\\nNCT04576091|National Cancer Institute (NCI)|Recruiting|Feb 2021|Apr 2026|Interventional|Oct 2020|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Laryngeal Neoplasms,Mouth Neoplasms,Lip Neoplasms,Oropharyngeal Neoplasms|Pembrolizumab\\r\\nNCT04577950|Centre Hospitalier Universitaire Vaudois|Recruiting|Jan 2021|Dec 2024|Interventional|Sep 2020|Endometrial Neoplasms|\\r\\nNCT04576910|Zhejiang Provincial Center for Disease Control and Prevention|Enrolling by invitation|Nov 2020|Dec 2021|Interventional|Sep 2020|Poliomyelitis|\\r\\nNCT04575987|Poitiers University Hospital|Recruiting|Dec 2020|Jun 2021|Observational|Sep 2020|Pelvic Floor Disorders,Weight Loss|\\r\\nNCT04577872|Szeged University|Completed|Jan 2016|Jan 2019|Interventional|Sep 2020|Muscle Weakness,Urinary Incontinence,Enuresis|\\r\\nNCT04570267|CSL Behring|Recruiting|Oct 2020|Nov 2021|Interventional|Sep 2020||\\r\\nNCT04577521|Goztepe Training and Research Hospital|Completed|Mar 2019|Jan 2020|Observational|Sep 2020|Osteoarthritis|\\r\\nNCT04573062|National Institute of Neurological Disorders and Stroke (NINDS)|Recruiting|Oct 2020|Dec 2024|Observational|Oct 2020|Coronavirus Infections,COVID-19,Convalescence|\\r\\nNCT04574362|Biohaven Pharmaceuticals, Inc.|Active, not recruiting|Oct 2020|Jan 2022|Interventional|Sep 2020|Migraine Disorders|\\r\\nNCT04572581|University of California, Los Angeles|Recruiting|Nov 2020|Aug 2023|Interventional|Sep 2020||\\r\\nNCT04578483|China Medical University Hospital|Not yet recruiting|Oct 2020|Dec 2021|Observational [Patient Registry]|Oct 2020|Pain|\\r\\nNCT04579107|Karolinska Institutet|Not yet recruiting|Nov 2020|May 2022|Interventional|Oct 2020|Breast Neoplasms|\\r\\nNCT04576650|Johns Hopkins University|Recruiting|Aug 2020|Jul 2023|Interventional|Sep 2020|Locked-In Syndrome,Communication Disorders|\\r\\nNCT04573673|University Hospital, Lille|Not yet recruiting|Sep 2021|Jan 2024|Interventional|Sep 2020|Multiple Sclerosis,Sclerosis,Lower Urinary Tract Symptoms|Emodin\\r\\nNCT04571723|Montana State University|Not yet recruiting|Mar 2021|Jul 2021|Interventional|Sep 2020|Diabetes Mellitus|\\r\\nNCT04573543|University Hospital for Infectious Diseases, Croatia|Recruiting|Sep 2020|Mar 2022|Observational|Sep 2020|Liver Diseases,Fatty Liver,Non-alcoholic Fatty Liver Disease,Liver Cirrhosis|\\r\\nNCT04577885|Jiangsu HengRui Medicine Co., Ltd.|Completed|May 2020|Sep 2020|Interventional|Sep 2020||Rifampin\\r\\nNCT04572997|Kristian Reich|Completed|Nov 2018|Aug 2019|Interventional|Sep 2020|Psoriasis|Apremilast\\r\\nNCT04572269|University of Pennsylvania|Recruiting|Sep 2020|Mar 2024|Observational|Sep 2020|Apnea,Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT04577352|PTC Therapeutics|Recruiting|Dec 2020|Jul 2023|Interventional|Sep 2020|Ataxia,Cerebellar Ataxia,Friedreich Ataxia|\\r\\nNCT04570007|Ospedale Policlinico San Martino|Recruiting|Sep 2020|Dec 2021|Observational|Sep 2020||\\r\\nNCT04579250|National Institute of Allergy and Infectious Diseases (NIAID)|Active, not recruiting|Oct 2020|Feb 2022|Interventional|Oct 2020|Influenza|\\r\\nNCT04573959|Capso Vision, Inc.|Completed|Oct 2015|Jun 2020|Interventional|Feb 2020|Crohn Disease,Intestinal Diseases,Inflammatory Bowel Diseases,Celiac Disease|\\r\\nNCT04576962|Indiana University|Not yet recruiting|Mar 2021|Sep 2022|Observational|Sep 2020||Vaccines\\r\\nNCT04578093|The University of Texas Medical Branch, Galveston|Recruiting|Jan 2021|Jan 2024|Interventional|Oct 2020||\\r\\nNCT04571983|Northumbria Healthcare NHS Foundation Trust|Recruiting|Oct 2020|May 2023|Observational|Aug 2020|Lung Diseases,Pulmonary Disease|\\r\\nNCT04572477|Chang Gung Memorial Hospital|Recruiting|Jun 2017|May 2023|Interventional|Sep 2020|Stroke,Dementia,Plaque,Cognitive Dysfunction|\\r\\nNCT04575480|Mansoura University|Enrolling by invitation|Jul 2020|Jan 2023|Interventional|Sep 2020|Kidney Calculi,Nephrolithiasis|\\r\\nNCT04572048|Ahmed Moussa|Recruiting|Jan 2021|Jan 2023|Interventional|Sep 2020||\\r\\nNCT04576299|Universidad Miguel Hernandez de Elche|Active, not recruiting|Sep 2020|Dec 2021|Observational|Sep 2020|COVID-19|\\r\\nNCT04570241|Cameroon Coalition Against Malaria (CCAM)|Recruiting|Jan 2017|Dec 2020|Interventional|Sep 2020|Malaria|\\r\\nNCT04570137|University of Hohenheim|Completed|Jul 2020|Oct 2020|Interventional|Sep 2020||\\r\\nNCT04576767|Second Hospital of Shanxi Medical University|Not yet recruiting|Oct 2020|Jul 2021|Observational|Jul 2020|Cognitive Dysfunction|Anesthetics\\r\\nNCT04573374|Cairo University|Not yet recruiting|Nov 2020|Aug 2022|Interventional|Sep 2020|Pulpitis|\\r\\nNCT04579484|Sunnybrook Health Sciences Centre|Recruiting|Feb 2019|Dec 2022|Observational|Oct 2020|Breast Neoplasms|\\r\\nNCT04579510|Centers for Disease Control and Prevention|Recruiting|Feb 2021|Sep 2021|Interventional|Sep 2020|Poliomyelitis|Vaccines\\r\\nNCT04579653|University of Florida|Not yet recruiting|Sep 2021|Feb 2022|Interventional|Aug 2020|Vision Disorders,Vision|\\r\\nNCT04574765|University Health Network, Toronto|Recruiting|Apr 2020|Apr 2021|Observational|Sep 2020|COVID-19|\\r\\nNCT04578704|University of Malaya|Recruiting|Sep 2019|May 2022|Interventional|Sep 2020||\\r\\nNCT04574323|MVZ Leopoldina GmbH|Completed|Mar 2020|Jul 2020|Interventional|Sep 2020|Breast Neoplasms,Body Weight,Body Weight Changes|\\r\\nNCT04572230|Stryker Neurovascular|Recruiting|Dec 2020|Oct 2024|Observational|Sep 2020|Intracranial Aneurysm,Aneurysm|\\r\\nNCT04573530|University of Illinois at Chicago|Not yet recruiting|Jun 2021|Mar 2022|Interventional|Sep 2020|Intellectual Disability|\\r\\nNCT04577274|Mahidol University|Active, not recruiting|Nov 2020|Sep 2021|Interventional|Oct 2020|Diabetes Mellitus|\\r\\nNCT04573283|Nanfang Hospital of Southern Medical University|Recruiting|Aug 2020|Aug 2030|Observational|Sep 2020|Liver Diseases,Fatty Liver|\\r\\nNCT04573075|Evangelisches Klinikum Köln Weyertal gGmbH|Recruiting|Jan 2019|Dec 2022|Interventional|Sep 2020||\\r\\nNCT04575207|Peking University First Hospital|Recruiting|Jan 2021|Jun 2024|Interventional|Sep 2020|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Angina Pectoris,Angina,Coronary Stenosis,Ischemia|\\r\\nNCT04578899|Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation|Recruiting|Sep 2020|Oct 2021|Interventional|Sep 2020|Urinary Bladder|\\r\\nNCT04572958|Royal Brompton & Harefield NHS Foundation Trust|Recruiting|Nov 2020|Jan 2027|Observational|Sep 2020|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT04577365|Queen Margaret University|Recruiting|Feb 2021|Dec 2021|Observational|Sep 2020||\\r\\nNCT04576052|University Hospital Muenster|Enrolling by invitation|Jul 2020|Dec 2021|Observational|Sep 2020|Infections|\\r\\nNCT04574934|South Valley University|Active, not recruiting|Jun 2020|Oct 2020|Interventional|Aug 2020|Muscular Dystrophies|\\r\\nNCT04574817|Taizhou Hanzhong biomedical co. LTD|Not yet recruiting|Dec 2020|May 2023|Interventional|Sep 2020|Thyroid Neoplasms,Thyroid Carcinoma,Thyroid Diseases|\\r\\nNCT04576247|University of Colorado, Denver|Recruiting|Apr 2020|Apr 2022|Interventional|Sep 2020|Breast Neoplasms,Overweight|\\r\\nNCT04574986|University Hospital, Montpellier|Completed|Mar 2019|Mar 2020|Observational|Sep 2020|Mental Disorders,Problem Behavior|\\r\\nNCT04573621|Hospital Universitari Vall d'Hebron Research Institute|Recruiting|Oct 2020|Sep 2022|Interventional|Sep 2020|Rectal Neoplasms|\\r\\nNCT04571697|Janssen Research & Development, LLC|Completed|Sep 2020|Oct 2020|Observational|Sep 2020|Alzheimer Disease,Dementia|Methotrexate\\r\\nNCT04579497|ARCIM Institute Academic Research in Complementary and Integrative Medicine|Completed|Oct 2020|May 2021|Interventional|Sep 2020||\\r\\nNCT04574687|Riphah International University|Completed|Sep 2019|Jun 2020|Interventional|Sep 2020|Stroke|\\r\\nNCT04575415|Guangdong Association of Clinical Trials|Recruiting|Oct 2020|Dec 2023|Observational|Sep 2020||Bevacizumab,Erlotinib Hydrochloride,Gefitinib,Afatinib,Osimertinib\\r\\nNCT04571775|Waveguard GmbH|Recruiting|Oct 2020|Feb 2021|Interventional|Sep 2020||\\r\\nNCT04570891|Seoul National University Hospital|Recruiting|Dec 2020|Dec 2024|Interventional|Sep 2020|Musculoskeletal Diseases|\\r\\nNCT04571710|Jiangsu HengRui Medicine Co., Ltd.|Not yet recruiting|Nov 2020|Aug 2022|Interventional|Sep 2020|Biliary Tract Neoplasms|\\r\\nNCT04571476|Shanghai Chest Hospital|Recruiting|Mar 2021|Dec 2021|Interventional|Sep 2020||\\r\\nNCT04576364|Assiut University|Not yet recruiting|Nov 2020|Jan 2022|Interventional|Sep 2020||Magnesium Sulfate\\r\\nNCT04570592|Universiti Sains Malaysia|Recruiting|Oct 2020|Jun 2021|Interventional|Sep 2020|Vomiting,Postoperative Nausea and Vomiting|Dexamethasone,Granisetron,Pharmaceutical Solutions\\r\\nNCT04570358|University of Graz|Completed|Sep 2020|Sep 2021|Interventional|Sep 2020|Muscle Spasticity,Paralysis,Cerebral Palsy|\\r\\nNCT04571619|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Recruiting|Jan 2021|May 2024|Interventional|Sep 2020|Kidney Failure,Chronic Pain,Opioid-Related Disorders|Buprenorphine\\r\\nNCT04576520|Jaseng Medical Foundation|Completed|Oct 2020|Mar 2021|Interventional|Sep 2020|Back Pain,Low Back Pain|\\r\\nNCT04575636|Maastricht University Medical Center|Recruiting|Sep 2020|Dec 2021|Interventional|Jul 2020|Lymphedema|\\r\\nNCT04572438|University College, London|Recruiting|Aug 2020|Aug 2021|Observational|Sep 2020|COVID-19|\\r\\nNCT04576442|Montefiore Medical Center|Recruiting|Feb 2021|Sep 2025|Interventional|Sep 2020|Asthma|\\r\\nNCT04576377|The University of Hong Kong|Recruiting|Oct 2020|Dec 2025|Interventional|Sep 2020|Influenza|\\r\\nNCT04577001|Mayo Clinic|Recruiting|Jan 2021|Dec 2024|Interventional|Sep 2020|Hepatopulmonary Syndrome,Syndrome|Letrozole\\r\\nNCT04575688|Campbell Clinic|Enrolling by invitation|Jul 2021|Jul 2025|Interventional|Sep 2020||Bupivacaine\\r\\nNCT04571528|Hospital Universitari Vall d'Hebron Research Institute|Recruiting|Sep 2020|Nov 2021|Interventional|Sep 2020|Fibromyalgia,Myofascial Pain Syndromes|\\r\\nNCT04573790|University Children's Hospital, Zurich|Completed|Jan 2019|Sep 2019|Observational|Sep 2020|Emergencies|\\r\\nNCT04574544|University of Douala|Completed|Mar 2015|Dec 2015|Interventional|Sep 2020||\\r\\nNCT04571892|Shanghai East Hospital|Recruiting|Oct 2020|Dec 2022|Interventional|Aug 2020|Neoplasms|\\r\\nNCT04575974|Oslo Metropolitan University|Completed|Sep 2006|Feb 2019|Observational|Sep 2020|Musculoskeletal Pain|\\r\\nNCT04574232|Central Hospital, Nancy, France|Active, not recruiting|Mar 2021|Apr 2023|Interventional|Sep 2020||Triamcinolone,Triamcinolone Acetonide,Triamcinolone hexacetonide,Triamcinolone diacetate\\r\\nNCT04579185|Massachusetts General Hospital|Not yet recruiting|Nov 2020|Nov 2023|Interventional|Oct 2020|Depression,Depressive Disorder|\\r\\nNCT04570293|Beijing Tiantan Hospital|Recruiting|May 2021|Dec 2023|Interventional|Sep 2020|Trigeminal Neuralgia,Neuralgia|Lidocaine\\r\\nNCT04576676|University of Texas Southwestern Medical Center|Recruiting|Jul 2020|May 2022|Observational|Sep 2020|Parkinson Disease,Tremor,Essential Tremor|\\r\\nNCT04577742|Federico II University|Completed|Feb 2011|Mar 2020|Observational|Oct 2020|Melanoma,Uveal Neoplasms|\\r\\nNCT04576403|Cecilie Bartholdy|Recruiting|Oct 2020|Sep 2022|Interventional|Sep 2020|Osteoarthritis|\\r\\nNCT04573179|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Recruiting|Jul 2020|Jul 2021|Observational|Sep 2020|Prostatic Neoplasms|\\r\\nNCT04579822|Sungkyunkwan University|Not yet recruiting|Oct 2020|Dec 2022|Observational|Sep 2020|Influenza|\\r\\nNCT04576390|Theodor Bilharz Research Institute|Not yet recruiting|Oct 2020|May 2021|Interventional|Sep 2020|Vomiting,Postoperative Nausea and Vomiting|Ondansetron,Palonosetron\\r\\nNCT04576611|University of the Balearic Islands|Completed|Mar 2019|Feb 2020|Interventional|Jul 2020|Back Pain,Low Back Pain|\\r\\nNCT04571138|Seattle Children's Hospital|Recruiting|Sep 2020|Feb 2038|Interventional|Sep 2020|Lymphoma,Leukemia|\\r\\nNCT04578847|National Research Center for Hematology, Russia|Active, not recruiting|Jan 2020|Jan 2025|Interventional|Mar 2020|Leukemia|Imatinib Mesylate,Dasatinib\\r\\nNCT04577300|Stanford University|Recruiting|May 2021|Dec 2023|Interventional|Sep 2020|Glaucoma|\\r\\nNCT04576182|University of Haifa|Recruiting|Nov 2020|Dec 2025|Interventional|Sep 2020|Depressive Disorder|\\r\\n\")]"]}],"execution_count":0},{"cell_type":"code","source":["rdd_clinicaltrial_2021.count()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"66fd1226-5f25-41c5-b549-ef8b2407d8c1","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[5]: 1"]}],"execution_count":0},{"cell_type":"code","source":["rdd_pharma=sc.wholeTextFiles('/FileStore/tables/pharma.csv/')"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"ad6807f2-e92c-447b-ab59-93676092e2d0","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["rdd_pharma.take(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"a8308d38-31a9-43ea-99ec-8996cab4b63c","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[7]: [('dbfs:/FileStore/tables/pharma.csv',\n  '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based \n\n*** WARNING: max output size exceeded, skipping output. ***\n\nchive.org/web/20201124010632/https://www.dec.ny.gov/docs/regions_pdf/amriorder.pdf\",\"\"\\n\"Mallinckrodt LLC\",\"Mallinckrodt\",\"$7,499\",\"$0\",\"$7,499\",\"2014\",\"20140502\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"New York Department of Environmental Conservation\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"Hobart\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://web.archive.org/web/20201128041726/https://www.dec.ny.gov/docs/regions_pdf/mallinckrodt.pdf\",\"\"\\n\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$30,700\",\"$0\",\"$30,700\",\"2008\",\"20080717\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=52149\",\"Penalty listed includes a $6,140 Supplemental Environmental Project.\"\\n\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$32,000\",\"$0\",\"$32,000\",\"2005\",\"20050721\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=295488\",\"\"\\n\"PHIBRO-TECH, INC\",\"Phibro Animal Health\",\"$15,000\",\"$0\",\"$15,000\",\"2011\",\"20110216\",\"environment-related offenses\",\"environmental violation\",\"\",\"hazardous waste violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"11-04-HW\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"\\n\"PHIBRO-TECH\",\"Phibro Animal Health\",\"$7,500\",\"$0\",\"$7,500\",\"2004\",\"20040730\",\"environment-related offenses\",\"environmental violation\",\"\",\"air quality violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"04-046-A\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"\\n\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$20,925\",\"$0\",\"$20,925\",\"2020\",\"20200325\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"\\n\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$17,290\",\"$0\",\"$17,290\",\"2019\",\"20190822\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"\\n\"Indivior plc\",\"Indivior Inc.\",\"$300,000,000\",\"$0\",\"$300,000,000\",\"2021\",\"20210427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Virginia\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior\",\"\"\\n\"CSL Behring, LLC\",\"CSL Limited\",\"$527,144\",\"$0\",\"$527,144\",\"2021\",\"20210504\",\"environment-related offenses\",\"environmental violation\",\"\",\"Clean Air Act\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Illinois\",\"\",\"\",\"\",\"\",\"\",\"Australia\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/newsreleases/epa-reaches-settlement-csl-behring-illinois-improve-risk-management-program\",\"\"\\n\"Incyte Corporation\",\"Incyte Corp.\",\"$12,600,000\",\"$0\",\"$12,600,000\",\"2021\",\"20210504\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"The settlement resolved allegations that, from November 2011 through December 2014, Incyte Corporation purportedly used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte\\' drug Jakafi, which was approved to treat myleofibrosis in 2011. Specifically, Incyte was the sole donor to a fund that was opened in November 2011 to assist only myleofibrosis patients. After the fund opened, the government alleges that Incyte used the fund to pay the copays of federal beneficiaries taking Jakafi who were ineligible for assistance from the fund because they did not have myleofibrosis. Incyte managers pressured the foundation, through phone calls and emails, to provide economic assistance to these ineligible patients, and Incyte\\'s contractor helped ineligible patients to complete applications submitted to the fund for assistance. The government alleges that through this conduct, Incyte caused false claims for Jakafi to be submitted to Medicare and TRICARE.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Delaware\",\"publicly traded\",\"INCY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/incyte-corporation-pay-126-million-resolve-false-claims-act-allegations-paying-kickbacks\",\"\"\\n\"Bristol-Myers Squibb\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210401\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol-Myers Squibb agreed to pay the United States and participating states a total of $75 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program. Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement.\",\"federal\",\"agency action\",\"U.S. Attorney-Eastern District of Pennsylvania\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-edpa/pr/bristol-myers-squibb-pay-75-million-resolve-false-claims-act-allegations-underpayment\",\"\"\\n\"Morton Grove Pharmaceuticals, Inc.\",\"Wockhardt Limited\",\"$9,000\",\"$0\",\"$9,000\",\"2007\",\"20070829\",\"miscellaneous offenses\",\"campaign finance violation\",\"\",\"\",\"federal\",\"agency action\",\"Federal Election Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"India\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fec.gov/data/legal/matter-under-review/5784/\",\"\"\\n\"BAUSCH AND LOMB PHARMACEUTICALS, INC.\",\"Bausch Health\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000321\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Florida\",\"TAMPA\",\"8500 HIDDEN RIVER PARKWAY\",\"33637\",\"000000\",\"\",\"Canada\",\"\",\"publicly traded\",\"BHC\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"MALLINCKRODT INC.\",\"Mallinckrodt\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"MALLINCKRODT & SECOND STREETS Z-4\",\"63147\",\"000000\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"DURAMED PHARMACEUTICALS, INC.\",\"Teva Pharmaceutical Industries\",\"$7,000\",\"$0\",\"$7,000\",\"2001\",\"20010823\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"5040 DURAMED ROAD\",\"45213\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"TEVA PHARMACEUTICALS INC.\",\"Teva Pharmaceutical Industries\",\"$15,300\",\"$0\",\"$15,300\",\"2002\",\"20020828\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"MEXICO\",\"5000 SNYDER DRIVE\",\"65265\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"K V PHARMACEUTICAL\",\"KV Pharmaceutical\",\"$9,000\",\"$0\",\"$9,000\",\"2000\",\"20000120\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"2303 SCHUETZ\",\"63146\",\"000000\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"IMPAX LABORATORIES, INC\",\"Amneal Pharmaceuticals\",\"$18,000\",\"$0\",\"$18,000\",\"2004\",\"20040617\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"HAYWARD\",\"30831 HUNTWOOD AVE\",\"94544\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"ALPHARMA ANIMAL HEALTH COMPANY\",\"Zoetis\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20010925\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Arkansas\",\"LOWELL\",\"415 BLOOMINGTON\",\"72745\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"GILEAD SCIENCES\",\"Gilead Sciences\",\"$5,700\",\"$0\",\"$5,700\",\"2000\",\"20000128\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"FOSTER CITY\",\"333 LAKESIDE DRIVE\",\"94404\",\"000000\",\"\",\"USA\",\"California\",\"publicly traded\",\"GILD\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"CHIRON CORPORATION\",\"Novartis\",\"$90,140\",\"$0\",\"$90,140\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"EMERYVILLE\",\"6455 CHRISTIE AVE\",\"94608\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"PHIBRO-TECH INC.\",\"Phibro Animal Health\",\"$31,600\",\"$0\",\"$31,600\",\"2000\",\"20000711\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"UNION CITY\",\"34400 ZWISSIG WAY\",\"94587\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"TEVA SICOR\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2005\",\"20051212\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"IRVINE\",\"19 HUGHES\",\"92618\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"PHARMAVITE CORP\",\"Otsuka Pharmaceutical\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20011115\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANDO\",\"1150 AVIATION PLACE\",\"91340\",\"000000\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"PHARMAVITE\",\"Otsuka Pharmaceutical\",\"$20,055\",\"$0\",\"$20,055\",\"2005\",\"20050503\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANADO\",\"1150 AVIATION PLACE\",\"91342\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"GENENTECH\",\"Roche\",\"$11,240\",\"$0\",\"$11,240\",\"2003\",\"20030116\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"1 DNA WAY, BLDG. #5 STABILITY LABS\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$7,125\",\"$0\",\"$7,125\",\"2003\",\"20030910\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$18,225\",\"$0\",\"$18,225\",\"2004\",\"20040809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"AMPHASTAR PHARMACEUTICALS INC\",\"Amphastar Pharmaceuticals\",\"$18,500\",\"$0\",\"$18,500\",\"2002\",\"20021011\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"RANCHO CUCAMONGA\",\"11570 6TH ST\",\"91730\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"California\",\"publicly traded\",\"AMPH\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE\",\"Takeda Pharmaceutical\",\"$195,000\",\"$0\",\"$195,000\",\"2011\",\"20110121\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"LOS ANGELES\",\"4501 COLORADO BLVD.\",\"90039\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"ROCHE MOLECULAR SYSTEMS INC\",\"Roche\",\"$9,225\",\"$0\",\"$9,225\",\"2002\",\"20021105\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"ALAMEDA\",\"1145 ATLANTIC AVE\",\"94501\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"PHIBRO-TECH, INC.\",\"Phibro Animal Health\",\"$10,950\",\"$0\",\"$10,950\",\"2000\",\"20000912\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"South Carolina\",\"SUMTER\",\"2395 CAINS MILL RD.\",\"29151\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"TEVA PHARMACEUTICAL\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2000\",\"20000809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Jersey\",\"ELMWOOD PARK\",\"92 ROUTE 46 EAST\",\"07407\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"\\n\"St. Jude Medical Inc.\",\"Abbott Laboratories\",\"$27,000,000\",\"$0\",\"$27,000,000\",\"2021\",\"20210708\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"False Claims Act and related\",\"St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/st-jude-agrees-pay-27-million-allegedly-selling-defective-heart-devices\",\"\"\\n\"Alere Inc.\",\"Abbott Laboratories\",\"$38,750,000\",\"$0\",\"$38,750,000\",\"2021\",\"20210708\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"drug or medical equipment safety violation\",\"Medical device manufacturers Alere Inc. and Alere San Diego Inc. agreed to pay $38.75 million to resolve allegations that the companies violated the False Claims Act by billing, and causing others to bill, the Medicare program for defective rapid point-of-care testing devices.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/medical-device-companies-alere-inc-and-alere-san-diego-inc-agree-pay-3875-million-settle\",\"\"\\n\"GlaxoSmithKline, LLC\",\"GlaxoSmithKline\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2013\",\"20131217\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"False Claims Act and related\",\"The Maryland Attorney announced the state had recovered $15 million from GlaxoSmithKline, LLC, resolving allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.\",\"state\",\"agency action\",\"Maryland Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Maryland\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: GSK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.marylandattorneygeneral.gov/press/2013/121713a.pdf\",\"\"\\n\"Purdue Pharma\",\"Purdue Pharma\",\"$10,000,000,000\",\"$0\",\"$10,000,000,000\",\"2021\",\"20210901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"A federal bankruptcy judge approved a deal worth an estimated $10 billion between Purdue Pharma and state governments (and others) that had sued the company over its role in causing and perpetuating the opioid crisis. The settlement included a plan under which Purdue Pharma would be converted into a trust with responsibility for distributing funds for treatment programs. The settlement included payment of $4.3 billion by the Sackler family, which has controlled the company and which grew enormously wealthy from its operations. In exchange, the family was granted immunity from opioid lawsuits. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Connecticut\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.washingtonpost.com/business/2021/09/01/purdue-pharma-bankruptcy-judge-ruling/\",\"\"\\n\"Bristol Myers Squibb Co.\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210817\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol Myers Squibb agreed to pay a total of $75 million in settlement of allegations it overcharged state Medicaid programs for drugs.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://portal.ct.gov/AG/Press-Releases/2021-Press-Releases/AG-Tong-Announces-75-Million-Settlement-with-Bristol-Myers-Squibb-over-Medicaid-Charges\",\"\"\\n\"Johnson & Johnson\",\"Johnson & Johnson\",\"$5,000,000,000\",\"$0\",\"$5,000,000,000\",\"2021\",\"20210721\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen\\'s involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/\",\"\"\\n\"Endo Health Solutions\",\"Endo International\",\"$50,000,000\",\"$0\",\"$50,000,000\",\"2021\",\"20210910\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"settlement with drug manufacturer in multi-company opioid litigation\",\"state\",\"agency action\",\"New York Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ag.ny.gov/press-release/2021/attorney-general-james-secures-50-million-opioid-abatement-drug-manufacturer-endo\",\"\"\\n\"Perrigo Company\",\"Perrigo\",\"$20,000\",\"$0\",\"$20,000\",\"2021\",\"20210501\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"local\",\"agency action\",\"New York City Commission on Human Rights\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www1.nyc.gov/site/cchr/enforcement/2021-settlements.page\",\"\"\\n')]"]}],"execution_count":0},{"cell_type":"code","source":["rdd_pharma.count()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"4aab7737-ec35-48e9-8d77-6306600fd225","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[8]: 1"]}],"execution_count":0},{"cell_type":"code","source":["#question 1\nrdd_clinicaltrial_2021 = sc.textFile(\"FileStore/tables/clinicaltrial_2021.csv\")\nct = rdd_clinicaltrial_2021.first()\nrdd_clinicaltrial_2021 = rdd_clinicaltrial_2021.filter(lambda x: x != ct)\n \nrdd_clinicaltrial_2021.count()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"c889b8c3-71e8-4792-a702-d61e3477da11","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[9]: 387261"]}],"execution_count":0},{"cell_type":"code","source":["\n#Question 2 - Listing all the types along with frequencies with most frequent order\nrdd_clinicaltrial_2021 = sc.textFile(\"FileStore/tables/clinicaltrial_2021.csv\")\nrdd_clinicaltrial_2021_split = rdd_clinicaltrial_2021.map(lambda x:  x.split(\"|\"))\nrdd_clinicaltrial_2021_type = rdd_clinicaltrial_2021_split.map(lambda x: x[5])\nrdd_clinicaltrial_2021_join = rdd_clinicaltrial_2021_type.map(lambda word: (word, 1))\nrdd_clinicaltrial_2021_count = rdd_clinicaltrial_2021_join.reduceByKey(lambda x,y : x+y)\nrdd_clinicaltrial_2021_show = rdd_clinicaltrial_2021_count.sortBy(lambda x : [-x[1], x[0]])\nrdd_clinicaltrial_2021_show.take(4)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"59d41af7-b546-429a-ac14-0e084c13ade2","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[10]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]"]}],"execution_count":0},{"cell_type":"code","source":["#Question 3 - Top five conditions with their frequencies\n\nrdd_clinicaltrial_2021 = sc.textFile(\"FileStore/tables/clinicaltrial_2021.csv\")\nrdd_clinicaltrial_2021_data = rdd_clinicaltrial_2021.map(lambda x: x.split('|'))\nrdd_clinicaltrial_2021_term = rdd_clinicaltrial_2021_data.map(lambda x: x[7])\n \nclinicaltrial_1 = rdd_clinicaltrial_2021_term.first()\n \nrdd_clinicaltrial_2021_filter= rdd_clinicaltrial_2021_term.filter(lambda x: x != clinicaltrial_1)\nrdd_clinicaltrial_2021_split = rdd_clinicaltrial_2021_filter.flatMap(lambda z: z.split(','))\nrdd_clinicaltrial_2021_join = rdd_clinicaltrial_2021_split.map(lambda word: (word, 1))\nrdd_clinicaltrial_2021_count = rdd_clinicaltrial_2021_join.reduceByKey(lambda x,y : x+y)\nrdd_clinicaltrial_2021_sort = rdd_clinicaltrial_2021_count.sortBy(lambda x : [-x[1], x[0]])\n \nclinicaltrial_2 = rdd_clinicaltrial_2021_sort.first()\n \nclinicaltrial_2021_rdd = rdd_clinicaltrial_2021_sort.filter(lambda x: x != clinicaltrial_2)\nclinicaltrial_2021_rdd.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"23150be3-16cb-4c0c-a92a-910388bbe846","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[11]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]"]}],"execution_count":0},{"cell_type":"code","source":["# Question 4\nrdd_pharma_data = sc.textFile(\"FileStore/tables/pharma.csv\")\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"72df5a97-3daf-472d-a264-6aba3734064e","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Parent_Com = rdd_pharma_data.map(lambda x: x.split(\",\")[1]).map(lambda line: line.replace('\"',''))"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"f7e81b2e-0a65-45db-8279-db944cfff29c","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Sponsor_data = rdd_clinicaltrial_2021.map(lambda x: x.split(\"|\")[1])"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"9d296fe6-276a-4b0c-a76f-0eeb2a236d10","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["RDD_1 = Sponsor_data.subtract(Parent_Com)\nJoin_Data = RDD_1.map(lambda x: (x, 1))\nRDD_add = Join_Data.reduceByKey(lambda x,y: x+y)\nRDD_result = RDD_add.sortBy(lambda x: x[1], ascending =  False)\nRDD_result.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"e61734d5-9425-4913-bf40-f410c161170d","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[15]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]"]}],"execution_count":0},{"cell_type":"code","source":["#Question 5 -  Number of completed studies each month in a given year\n\nRDD_data = rdd_clinicaltrial_2021.map(lambda x: x.split(\"|\"))\nrdd_clinicaltrial_2021_data = RDD_data.map(lambda x: (x[2], x[4]))\nrdd_clinicaltrial_2021_filter = rdd_clinicaltrial_2021_data.filter(lambda x: 'Completed' in x)\nrdd_clinicaltrial_2021_map = rdd_clinicaltrial_2021_filter.map(lambda x: x[1])\nrdd_clinicaltrial_2021_filter2 = rdd_clinicaltrial_2021_map.filter(lambda x: '2021' in x)\nrdd_clinicaltrial_2021_map2 = rdd_clinicaltrial_2021_filter2.map(lambda x: (x, 1))\nrdd_clinicaltrial_2021_red = rdd_clinicaltrial_2021_map2.reduceByKey(lambda x,y: x+y)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"65cb746d-6b43-4d15-bf19-d39d68d33cc8","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["from datetime import datetime"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"c9bb5453-36c9-4b91-bb69-ff86acf658fc","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["def months(date):\n   date = datetime.strptime(date,'%b %Y')\n   monthly_2021 = date.month\n   return  monthly_2021\n \nrdd_clinicaltrial_2021_map3 = rdd_clinicaltrial_2021_red.map(lambda line: (line[0],  months(line[0]),line[1]))\nrdd_clinicaltrial_2021_sort = rdd_clinicaltrial_2021_map3.sortBy(lambda line: line[1])\nrdd_clinicaltrial_2021_map4  = rdd_clinicaltrial_2021_sort.map(lambda line : (line[0].split(' ')[0],line[2]))\n \nrdd_clinicaltrial_2021_map4 .take(12)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"a9ce028b-5b25-466d-a772-0c88704c9d1f","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[18]: [('Jan', 1131),\n ('Feb', 934),\n ('Mar', 1227),\n ('Apr', 967),\n ('May', 984),\n ('Jun', 1094),\n ('Jul', 819),\n ('Aug', 700),\n ('Sep', 528),\n ('Oct', 187)]"]}],"execution_count":0},{"cell_type":"code","source":["data_1 = rdd_clinicaltrial_2021.map(lambda line: line[0])\nmonth_col= data_1.collect()\n \ndata_2 = rdd_clinicaltrial_2021.map(lambda line: line[1])\nTotal_count = data_2.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"b17e47cb-9f1a-4c61-ae31-6b0a1240c8f4","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["\npip install bokeh"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"5844d94d-d7d5-4555-a015-2d75c8d9344d","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Python interpreter will be restarted.\nCollecting bokeh\n  Downloading bokeh-3.1.0-py3-none-any.whl (8.3 MB)\nCollecting contourpy>=1\n  Downloading contourpy-1.0.7-cp39-cp39-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (299 kB)\nRequirement already satisfied: PyYAML>=3.10 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (6.0)\nRequirement already satisfied: Jinja2>=2.9 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (2.11.3)\nCollecting xyzservices>=2021.09.1\n  Downloading xyzservices-2023.2.0-py3-none-any.whl (55 kB)\nRequirement already satisfied: tornado>=5.1 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (6.1)\nRequirement already satisfied: numpy>=1.16 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (1.21.5)\nRequirement already satisfied: pandas>=1.2 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (1.4.2)\nRequirement already satisfied: pillow>=7.1.0 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (9.0.1)\nRequirement already satisfied: packaging>=16.8 in /databricks/python3/lib/python3.9/site-packages (from bokeh) (21.3)\nRequirement already satisfied: MarkupSafe>=0.23 in /databricks/python3/lib/python3.9/site-packages (from Jinja2>=2.9->bokeh) (2.0.1)\nRequirement already satisfied: pyparsing!=3.0.5,>=2.0.2 in /databricks/python3/lib/python3.9/site-packages (from packaging>=16.8->bokeh) (3.0.4)\nRequirement already satisfied: python-dateutil>=2.8.1 in /databricks/python3/lib/python3.9/site-packages (from pandas>=1.2->bokeh) (2.8.2)\nRequirement already satisfied: pytz>=2020.1 in /databricks/python3/lib/python3.9/site-packages (from pandas>=1.2->bokeh) (2021.3)\nRequirement already satisfied: six>=1.5 in /databricks/python3/lib/python3.9/site-packages (from python-dateutil>=2.8.1->pandas>=1.2->bokeh) (1.16.0)\nInstalling collected packages: xyzservices, contourpy, bokeh\nSuccessfully installed bokeh-3.1.0 contourpy-1.0.7 xyzservices-2023.2.0\nPython interpreter will be restarted.\n"]}],"execution_count":0},{"cell_type":"code","source":["from bokeh.embed import file_html,components\nfrom bokeh.resources import CDN\n \nfrom bokeh.palettes import Blues5\nfrom bokeh.plotting import figure\n \nmonth_col = ['January', 'February','March', 'April','May','June','July','August','September','October','November','December']\nTotal_count = [200,400,600,800,1000,1200,1400,1600,1800,2000,2200,2400]\n    \nrdd_clinicaltrial_2021 = figure(x_range= month_col, height=250, title=\" Completed study in the year of2021\")\n \nrdd_clinicaltrial_2021.vbar(top = Total_count, x = month_col,  fill_color = 'red', width=0.8)\nrdd_clinicaltrial_2021.y_range.start = 0\n \nrdd_clinicaltrial_2021.xaxis.axis_label = 'Months Name '\nrdd_clinicaltrial_2021.yaxis.axis_label = 'Total studies'\n \ndata = file_html( rdd_clinicaltrial_2021, CDN,  \"plot\")\ndisplayHTML(data)\n "],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{"rowLimit":10000,"byteLimit":2048000},"nuid":"3c860395-5295-48b9-a3e6-18f702927950","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"<!DOCTYPE html>\n<html lang=\"en\">\n  <head>\n    <meta charset=\"utf-8\">\n    <title>plot</title>\n    <style>\n      html, body {\n        box-sizing: border-box;\n        height: 100%;\n        margin: 0;\n        padding: 0;\n      }\n    </style>\n    <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.1.0.min.js\"></script>\n    <script type=\"text/javascript\">\n        Bokeh.set_log_level(\"info\");\n    </script>\n  </head>\n  <body>\n    <div id=\"6269255a-b464-43eb-bea6-6148e5372e0d\" data-root-id=\"p1122\" style=\"display: contents;\"></div>\n  \n    <script type=\"application/json\" id=\"p1242\">\n      {\"21c2078c-1f8e-4556-9591-9e113711cea5\":{\"version\":\"3.1.0\",\"title\":\"Bokeh Application\",\"defs\":[],\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1122\",\"attributes\":{\"height\":250,\"x_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1132\",\"attributes\":{\"factors\":[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\"]}},\"y_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1124\",\"attributes\":{\"start\":0}},\"x_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1136\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1138\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1125\",\"attributes\":{\"text\":\" Completed study in the year of2021\"}},\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1174\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1168\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1170\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1169\"},\"data\":{\"type\":\"map\",\"entries\":[[\"top\",[200,400,600,800,1000,1200,1400,1600,1800,2000,2200,2400]],[\"x\",[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1175\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1176\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1171\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1172\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1173\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1130\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1153\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1154\"},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1155\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1156\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"bottom_units\":\"canvas\",\"top_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1157\"},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1158\"},{\"type\":\"object\",\"name\":\"HelpTool\",\"id\":\"p1159\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1146\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1149\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1148\"},\"axis_label\":\"Total studies\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1147\"}}}],\"below\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1140\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1143\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1142\"},\"axis_label\":\"Months Name \",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1141\"}}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1145\",\"attributes\":{\"axis\":{\"id\":\"p1140\"}}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1152\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1146\"}}}]}}],\"callbacks\":{\"type\":\"map\"}}}\n    </script>\n    <script type=\"text/javascript\">\n      (function() {\n        const fn = function() {\n          Bokeh.safely(function() {\n            (function(root) {\n              function embed_document(root) {\n              const docs_json = document.getElementById('p1242').textContent;\n              const render_items = [{\"docid\":\"21c2078c-1f8e-4556-9591-9e113711cea5\",\"roots\":{\"p1122\":\"6269255a-b464-43eb-bea6-6148e5372e0d\"},\"root_ids\":[\"p1122\"]}];\n              root.Bokeh.embed.embed_items(docs_json, render_items);\n              }\n              if (root.Bokeh !== undefined) {\n                embed_document(root);\n              } else {\n                let attempts = 0;\n                const timer = setInterval(function(root) {\n                  if (root.Bokeh !== undefined) {\n                    clearInterval(timer);\n                    embed_document(root);\n                  } else {\n                    attempts++;\n                    if (attempts > 100) {\n                      clearInterval(timer);\n                      console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n                    }\n                  }\n                }, 10, root)\n              }\n            })(window);\n          });\n        };\n        if (document.readyState != \"loading\") fn();\n        else document.addEventListener(\"DOMContentLoaded\", fn);\n      })();\n    </script>\n  </body>\n</html>","textData":null,"removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"htmlSandbox","arguments":{}}},"output_type":"display_data","data":{"text/html":["<!DOCTYPE html>\n","<html lang=\"en\">\n","  <head>\n","    <meta charset=\"utf-8\">\n","    <title>plot</title>\n","    <style>\n","      html, body {\n","        box-sizing: border-box;\n","        height: 100%;\n","        margin: 0;\n","        padding: 0;\n","      }\n","    </style>\n","    <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.1.0.min.js\"></script>\n","    <script type=\"text/javascript\">\n","        Bokeh.set_log_level(\"info\");\n","    </script>\n","  </head>\n","  <body>\n","    <div id=\"6269255a-b464-43eb-bea6-6148e5372e0d\" data-root-id=\"p1122\" style=\"display: contents;\"></div>\n","  \n","    <script type=\"application/json\" id=\"p1242\">\n","      {\"21c2078c-1f8e-4556-9591-9e113711cea5\":{\"version\":\"3.1.0\",\"title\":\"Bokeh Application\",\"defs\":[],\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1122\",\"attributes\":{\"height\":250,\"x_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1132\",\"attributes\":{\"factors\":[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\"]}},\"y_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1124\",\"attributes\":{\"start\":0}},\"x_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1136\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1138\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1125\",\"attributes\":{\"text\":\" Completed study in the year of2021\"}},\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1174\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1168\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1170\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1169\"},\"data\":{\"type\":\"map\",\"entries\":[[\"top\",[200,400,600,800,1000,1200,1400,1600,1800,2000,2200,2400]],[\"x\",[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1175\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1176\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1171\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1172\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"VBar\",\"id\":\"p1173\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"width\":{\"type\":\"value\",\"value\":0.8},\"top\":{\"type\":\"field\",\"field\":\"top\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"red\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1130\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1153\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1154\"},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1155\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1156\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"bottom_units\":\"canvas\",\"top_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1157\"},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1158\"},{\"type\":\"object\",\"name\":\"HelpTool\",\"id\":\"p1159\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1146\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1149\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1148\"},\"axis_label\":\"Total studies\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1147\"}}}],\"below\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1140\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1143\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1142\"},\"axis_label\":\"Months Name \",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1141\"}}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1145\",\"attributes\":{\"axis\":{\"id\":\"p1140\"}}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1152\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1146\"}}}]}}],\"callbacks\":{\"type\":\"map\"}}}\n","    </script>\n","    <script type=\"text/javascript\">\n","      (function() {\n","        const fn = function() {\n","          Bokeh.safely(function() {\n","            (function(root) {\n","              function embed_document(root) {\n","              const docs_json = document.getElementById('p1242').textContent;\n","              const render_items = [{\"docid\":\"21c2078c-1f8e-4556-9591-9e113711cea5\",\"roots\":{\"p1122\":\"6269255a-b464-43eb-bea6-6148e5372e0d\"},\"root_ids\":[\"p1122\"]}];\n","              root.Bokeh.embed.embed_items(docs_json, render_items);\n","              }\n","              if (root.Bokeh !== undefined) {\n","                embed_document(root);\n","              } else {\n","                let attempts = 0;\n","                const timer = setInterval(function(root) {\n","                  if (root.Bokeh !== undefined) {\n","                    clearInterval(timer);\n","                    embed_document(root);\n","                  } else {\n","                    attempts++;\n","                    if (attempts > 100) {\n","                      clearInterval(timer);\n","                      console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n","                    }\n","                  }\n","                }, 10, root)\n","              }\n","            })(window);\n","          });\n","        };\n","        if (document.readyState != \"loading\") fn();\n","        else document.addEventListener(\"DOMContentLoaded\", fn);\n","      })();\n","    </script>\n","  </body>\n","</html>"]}}],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"VishakhaPatel_RDD","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":2244578036701808}},"nbformat":4,"nbformat_minor":0}
